Your browser doesn't support javascript.
loading
Diagnosed prevalence of Alzheimer's disease and related dementias in Medicare Advantage plans.
Jutkowitz, Eric; Bynum, Julie P W; Mitchell, Susan L; Cocoros, Noelle M; Shapira, Oren; Haynes, Kevin; Nair, Vinit P; McMahill-Walraven, Cheryl N; Platt, Richard; McCarthy, Ellen P.
Afiliação
  • Jutkowitz E; Department of Health Services Policy & Practice Brown University School of Public Health Providence Rhode Island 02912 USA.
  • Bynum JPW; Providence Veterans Affairs (VA) Medical Center Center of Innovation in Long Term Services and Supports Providence Rhode Island 02908 USA.
  • Mitchell SL; Department of Internal Medicine University of Michigan Ann Arbor Michigan USA.
  • Cocoros NM; Hebrew Senior Life Hinda and Arthur Marcus Institute for Aging Research Boston Massachusetts USA.
  • Shapira O; Department of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA.
  • Haynes K; Department of Population Medicine Harvard Pilgrim Health Care Institute Boston Massachusetts USA.
  • Nair VP; Department of Population Medicine Harvard Pilgrim Health Care Institute Boston Massachusetts USA.
  • McMahill-Walraven CN; Department of Scientific Affairs Health Core, Inc. Wilmington Delaware USA.
  • Platt R; Humana Healthcare Research Humana Inc. Louisville Kentucky USA.
  • McCarthy EP; Healthagen LLC part of the CVS Health family of companies Blue Bell Pennsylvania USA.
Alzheimers Dement (Amst) ; 12(1): e12048, 2020.
Article em En | MEDLINE | ID: mdl-32647744
ABSTRACT

INTRODUCTION:

One-third of Medicare beneficiaries are enrolled in Medicare Advantage (MA). Yet, little is known about MA beneficiaries diagnosed with Alzheimer's disease (AD) and AD-related dementias (AD/ADRD).

METHODS:

We calculated the prevalence of AD/ADRD diagnoses in 2014 and 2016 in three MA plans. We determined the demographic characteristics of beneficiaries diagnosed with AD/ADRD, and whether they disenrolled from the MA plan for any reason within 364 days from the index date.

RESULTS:

In 2014 and 2016, the overall prevalence of AD/ADRD diagnoses was 5.6% and 6.5%, respectively. In 2016, AD/ADRD beneficiaries were on average 82.4 (SD = 7.4) years of age, 61.8% female, and had multiple comorbidities. By 364 days post-index date, 32% of beneficiaries with AD/ADRD had disenrolled from their plan. The demographic characteristics of 2014 beneficiaries with diagnosed AD/ADRD were similar to their 2016 counterparts.

DISCUSSION:

The prevalence of AD/ADRD diagnosis in MA is lower than rates reported in Medicare fee-for-service.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2020 Tipo de documento: Article